DOPA-sparing strategy in the treatment of young onset Parkinson’s disease
Context: Late onset Parkinson’s disease (LOPD) is a neurodegenerative disorder afflicting individuals of ages 60 and older. However, 5–10% of cases can begin earlier between the ages 20 to 40, and are classified as young onset Parkinson disease (YOPD). Aim: In turn, this study aims to observe the tr...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2016-01-01
|
Series: | Journal of Neurosciences in Rural Practice |
Subjects: | |
Online Access: | http://www.thieme-connect.de/DOI/DOI?10.4103/0976-3147.172155 |
id |
doaj-90251b6175a54b89b591f83d5fdc34ea |
---|---|
record_format |
Article |
spelling |
doaj-90251b6175a54b89b591f83d5fdc34ea2021-02-02T04:40:04ZengThieme Medical and Scientific Publishers Pvt. Ltd.Journal of Neurosciences in Rural Practice0976-31470976-31552016-01-01701676910.4103/0976-3147.172155DOPA-sparing strategy in the treatment of young onset Parkinson’s diseaseAbdul Qayyum Rana0Mohamad Saleh1Muhammad Saad Yousuf2Wasim Mansoor3Syed Hussaini4Maniza Rahman5Zohair Iqbal6Parkinson’s Clinic of Eastern Toronto and Movement Disorders Center, Toronto, CanadaParkinson’s Clinic of Eastern Toronto and Movement Disorders Center, Toronto, CanadaParkinson’s Clinic of Eastern Toronto and Movement Disorders Center, Toronto, CanadaParkinson’s Clinic of Eastern Toronto and Movement Disorders Center, Toronto, CanadaParkinson’s Clinic of Eastern Toronto and Movement Disorders Center, Toronto, CanadaParkinson’s Clinic of Eastern Toronto and Movement Disorders Center, Toronto, CanadaParkinson’s Clinic of Eastern Toronto and Movement Disorders Center, Toronto, CanadaContext: Late onset Parkinson’s disease (LOPD) is a neurodegenerative disorder afflicting individuals of ages 60 and older. However, 5–10% of cases can begin earlier between the ages 20 to 40, and are classified as young onset Parkinson disease (YOPD). Aim: In turn, this study aims to observe the trend in the choice of drug administered to patients with both YOPD and LOPD, with particular emphasis on this trend in its relation to the practice background of the neurologist. Settings and Design: A cross-sectional study was conducted in a community based Parkinson’s disease and movement disorder clinic. Statistical Analysis Used: Using a retrospective chart review data was obtained and analysed. Results: The results showed that 83% of general neurologists prescribed levodopa to their patients with YOPD, whereas movement-disorder specialists took a different approach altogether. They opted not to use levodopa and, in its stead, prescribed a mixture of alternate drugs.http://www.thieme-connect.de/DOI/DOI?10.4103/0976-3147.172155dopa-sparinggeneral neurologistlate-onset parkinson’s diseaselevodopamovement disorder specialistparkinson’s diseaseyoung onset parkinson’s disease |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Abdul Qayyum Rana Mohamad Saleh Muhammad Saad Yousuf Wasim Mansoor Syed Hussaini Maniza Rahman Zohair Iqbal |
spellingShingle |
Abdul Qayyum Rana Mohamad Saleh Muhammad Saad Yousuf Wasim Mansoor Syed Hussaini Maniza Rahman Zohair Iqbal DOPA-sparing strategy in the treatment of young onset Parkinson’s disease Journal of Neurosciences in Rural Practice dopa-sparing general neurologist late-onset parkinson’s disease levodopa movement disorder specialist parkinson’s disease young onset parkinson’s disease |
author_facet |
Abdul Qayyum Rana Mohamad Saleh Muhammad Saad Yousuf Wasim Mansoor Syed Hussaini Maniza Rahman Zohair Iqbal |
author_sort |
Abdul Qayyum Rana |
title |
DOPA-sparing strategy in the treatment of young onset Parkinson’s disease |
title_short |
DOPA-sparing strategy in the treatment of young onset Parkinson’s disease |
title_full |
DOPA-sparing strategy in the treatment of young onset Parkinson’s disease |
title_fullStr |
DOPA-sparing strategy in the treatment of young onset Parkinson’s disease |
title_full_unstemmed |
DOPA-sparing strategy in the treatment of young onset Parkinson’s disease |
title_sort |
dopa-sparing strategy in the treatment of young onset parkinson’s disease |
publisher |
Thieme Medical and Scientific Publishers Pvt. Ltd. |
series |
Journal of Neurosciences in Rural Practice |
issn |
0976-3147 0976-3155 |
publishDate |
2016-01-01 |
description |
Context: Late onset Parkinson’s disease (LOPD) is a neurodegenerative disorder afflicting individuals of ages 60 and older. However, 5–10% of cases can begin earlier between the ages 20 to 40, and are classified as young onset Parkinson disease (YOPD). Aim: In turn, this study aims to observe the trend in the choice of drug administered to patients with both YOPD and LOPD, with particular emphasis on this trend in its relation to the practice background of the neurologist. Settings and Design: A cross-sectional study was conducted in a community based Parkinson’s disease and movement disorder clinic. Statistical Analysis Used: Using a retrospective chart review data was obtained and analysed. Results: The results showed that 83% of general neurologists prescribed levodopa to their patients with YOPD, whereas movement-disorder specialists took a different approach altogether. They opted not to use levodopa and, in its stead, prescribed a mixture of alternate drugs. |
topic |
dopa-sparing general neurologist late-onset parkinson’s disease levodopa movement disorder specialist parkinson’s disease young onset parkinson’s disease |
url |
http://www.thieme-connect.de/DOI/DOI?10.4103/0976-3147.172155 |
work_keys_str_mv |
AT abdulqayyumrana dopasparingstrategyinthetreatmentofyoungonsetparkinsonsdisease AT mohamadsaleh dopasparingstrategyinthetreatmentofyoungonsetparkinsonsdisease AT muhammadsaadyousuf dopasparingstrategyinthetreatmentofyoungonsetparkinsonsdisease AT wasimmansoor dopasparingstrategyinthetreatmentofyoungonsetparkinsonsdisease AT syedhussaini dopasparingstrategyinthetreatmentofyoungonsetparkinsonsdisease AT manizarahman dopasparingstrategyinthetreatmentofyoungonsetparkinsonsdisease AT zohairiqbal dopasparingstrategyinthetreatmentofyoungonsetparkinsonsdisease |
_version_ |
1724305391405236224 |